ABOLOGIX obtains positive pre-clinical proof-of-concept results with its monoclonal antibody H225

- **Chimeric recombinant anti-JAM-C (Junction Adhesion Molecule C) mouse/rat monoclonal antibody H225 improved the survival of NOD/SCID mice inoculated with the Jeko-1 Mantle Cell Lymphoma (MCL) cell line**

- **Collectively the results show that blocking JAM-C could be a new therapeutic tool for the treatment of non-Hodgkin lymphomas (NHL)**

Geneva, Switzerland, July 24, 2019.
Abologix has obtained impressive data with its anti-JAM-C recombinant monoclonal antibody rH225 in an animal Mantle Cell Lymphoma (MCL) NOD/SCID mouse model

In this study the efficacy of rH225 was tested by assessing 1) the delayed mortality upon Jeko-1 MCL cell injection and 2) the reduction of Jeko-1 cells burden in the blood, spleen, lymph nodes, bone marrow and liver

rH225 delayed significantly the body weight loss and the onset of clinical disease signs in mice inoculated with Jeko-1 MCL cells. Survival of mice was significantly improved

Splenomegaly was observed in control antibody-treated animals, but not in rH225-treated mice, suggesting that the treatment effectively prevented spleen infiltration by Jeko-1 cells. Indeed, flow cytometry data revealed that treatment with rH225 significantly decreased the Jeko-1 burden in the spleen, liver, lymph nodes, blood and blood marrow.

“We are very pleased that antibody rH225 blocked infiltration in all lymphoid organs as well as in bone marrow. Inhibiting access of tumour cells to survival niches constitutes a potential new strategy for

lymphoma treatment", said Prof. Beat Imhof and Prof. Thomas Matthes", scientific co-founders of Abologix.

About Abologix

Abologix is a pre-clinical stage biopharmaceutical company developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule **JAM-C** and the extracellular matrix-related protein **Olfactomedin-like protein 3 (Olfml3)** for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Geneva and the Hôpitaux Universitaires de Genève.

Contact Information
Ignacio Faus, Chairman of the Board
Abologix. Sàrl
ignaciofaus@abologix.com